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tions between the patient numbers by months in physiotherapy care and the 
prevalence of fracture development. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
PMS126
A SySteMAtic Review of the coSt BuRden of Gout
Neves C, Shields GE, Beard S
BresMed, Sheffield, UK
Objectives: Gout, a chronic inflammatory arthritis, can result in extensive medi-
cal problems due to painful flares and joint damage resulting from the build-up of 
tophi (deposits of uric acid crystals). The prevalence of gout is rising, which is likely 
to increase the burden of the disease. We determined the current cost impacts 
of gout and identified key disease burden factors. We also aimed to highlight 
data gaps for further investigation. MethOds: A systematic literature review was 
conducted using the MEDLINE database and The Cochrane Library. Articles pub-
lished in English between January 2000 and July 2014 that reported the economic 
burden (in terms of either direct or indirect costs) were identified, and patient 
and cost data were collated, with key themes and data gaps identified. Results: 
Of the 323 studies identified, 13 primary studies were relevant to the economic 
burden of gout. Key variables included serum uric acid levels, presence of tophi 
and number of flares, which resulted in high healthcare resource use that was 
frequently attributed to hospitalisation and inpatient stay. The incremental direct 
cost of gout was reported to be up to US$21,467 per annum, in cases where patients 
were experiencing regular acute flares with the presence of tophi. cOnclusiOns: 
Patient-level costs associated with the treatment and clinical management of 
gout can be substantial, depending on disease severity. The identified studies 
were dominated by direct cost analyses; only three studies specifically considered 
indirect costs. There was a paucity of non-US data, and there was a lack of pub-
lished studies estimating the population-wide cost. Despite the limited published 
data, the review identified a growing number of publications in this area in the 
last 5 years, suggesting healthcare decision makers’ increasing awareness of the 
wider impacts of gout.
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Objectives: To compare the total value of payer’s expenditures on Cimzia (cer-
tolizumab pegol) and RoActemra (tocilizumab) in patients with severe rheumatoid 
arthritis estimated in the manufacturers’ Budget Impact Analyses (BIAs) submitted 
with the reimbursement applications to AOTMiT and actual expenditures of the 
National Health Fund (NHF). MethOds: Annual public payer’s expenditures esti-
mated in manufacturers’ BIAs for Cimzia and RoActemra and actual expenditures 
reported by the NHF were compared. RSSs were not taken into account. Analysed 
drugs were chosen on the basis of the same indication and financing through 
the same therapeutic programme in Poland. Actual expenditures and population 
size were taken from the financial reports of the NHF for the first and second 
year (actual data on 11 months for expenditures were extrapolated to one year) 
of reimbursement for each drug. Results: For drugs Cimzia and RoActemra in 
patients with severe rheumatoid arthritis, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 18,04 million PLN in 
the first year and 28,47 million PLN in the second year, and they were lower than 
the actual expenditures reported by the NHF: 20,03 million PLN and 36,51 million 
PLN, respectively. The expenditures estimated in BIAs were underestimated by 10% 
in the first year of reimbursement and 22% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was underestimated by 61% in the first year and 57% in the second year 
of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were underestimated in comparison to the real life expenditures of 
the NHF in Poland.
PMS128
PRevention of fRAGility fRActuReS in oSteoPoRotic PAtientS: cAn 
the SecondARy theRAPy helP contAin coStS foR AdMiSSionS? A 
RetRoSPective, oBSeRvAtionAl cASe contRol Study BASed on ASl 
PAviA’S AdMiniStRAtive dAtABASeS
Ronco GL1, Mirosa D2, Silvia V2, Carlo C2
1Emmonos S.A., Fenegro’, Italy, 2A.S.L. Pavia, Pavia, Italy
Objectives: Osteoporosis is one of the commonest bone diseases in which bone 
fragility is increased. There are several possibilities for the prevention of primary, 
secondary and tertiary osteoporosis but until now they have not been promoted 
enough and bone fragility is thought about only after the onset of a fracture (ter-
tiary prevention). Preventative strategies against osteoporosis can be aimed at 
either optimizing the peak bone mass obtained, or reducing the rate of bone 
loss. Optimization of peak bone mass may be more amenable to public health 
strategies. MethOds: A group of patients over 50 year old that has been treated 
with medicines included in the AIFA Note 79 during a period of 5 years is studied 
in comparison with a similar group that has not been treated with medicines 
included in the AIFA Note 79 for the same period time. For both groups are also 
extracted inpatient and outpatient medical records and medicine prescriptions. 
Only patients treated for at least three years are considered significant. To avoid 
confounding the resulting data were standardized and stratified. Results: The 
total expenditure for patients compliant with therapy who have had access to the 
hospital is less than twenty-eight percent compared to the total expenditure for 
patients not receiving therapy or not compliant. cOnclusiOns: Osteoporosis is 
undersupplied, even though they have a higher charlson-comorbidity index. Still, 
this study may not clarify whether this is due to costs or patient and physician 
preference.
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Objectives: The aim of this study is to perform gender specific analysis regard-
ing the persistence to antiosteoporotic drugs by using administrative data-
bases. MethOds: The data used for this study were obtained from outpatient 
drug prescriptions, hospital discharges and ambulatory care records collected 
from January 1, 2005 to December 31, 2008. The study was designed as a retrospec-
tive study cohort. Patients 60 years of age or older were included if at least one 
prescription for any antiosteoporotic drugs had been filled in between January 
1, 2006 and December 31, 2006. Persistence was defined as the length of time 
in days from the date of the index prescription to the date of discontinuation 
therapy. Discontinuation was evaluated by using the gap method. Results: 
The final cohort consisted of a total of 7,867 patients (87.2% women). The mean 
patient age for both genders at the index date was 74.5 years. About one-fifth of 
all subjects had experienced with spot therapy, but men were more likely than 
women to have a spot therapy experience (45.4% vs. 14.5%). Approximately 6% 
of all included patients were switchers: Switching rates were highest for males 
(18.9%) and lower for female (4.4%). The crude analysis of long-term gender per-
sistence showed a significant difference between women and men users: the 
relative number of persistence patients after 1 year was 66.4% in men and 44.7% 
in women. The Kaplan Meier plots of time to persistence start to differ for men 
vs women approximately 60 days after treatment start. cOnclusiOns: Gender 
differences in medication taking behaviour is a relevant issue in drug utilization 
studies. Our analysis showed that women are more likely to be non-persistent 
than men in osteoporosis ttherapy.
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Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by gender in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of the 
National Health Insurance Fund Administration (in Hungarian: OEP) involving 
the year of 2013. The activity list was provided by the rulebook on the application 
of the activity code list in out-patient care. The osteoporosis with pathological 
fractures is listed in the International Classification of Diseases (ICD) with code 
of M80. Population distribution was taken into account on the basis of the data 
of the Central Statistical Office from January 1st 2013. Results: Based on 151 
physiotherapy activities, the annual patient numbers accounted for 39725 per-
sons in the total population. The patient numbers accounted for 2544 persons 
for males and 37181 persons for females (10,000 per capita the patient num-
bers were 40 persons for the total population, 5 persons for males and 72 for 
females). cOnclusiOns: The higher patient numbers for females can be clearly 
associated with the prevalence of the basic disease. The total value for the patient 
numbers by months is higher caused by the aftercare of the same patients that 
still lasts in the following month. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
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Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by months in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of 
the National Health Insurance Fund Administration (in Hungarian: OEP) covering 
the year of 2013. The activity list was provided by the rulebook on the applica-
tion of the activity code list in out-patient care. The osteoporosis with patho-
logical fractures is listed in the International Classification of Diseases (ICD) 
with code of M80. Results: Based on 151 physiotherapy activities, the annual 
patient numbers accounted for 85142 persons in the total population by months. 
The patient numbers accounted for 5063 persons for males and 80079 persons 
for females. The patient numbers were 86 persons for the total population, 11 
persons for males and 154 for females per 10,000 capita. The patient numbers 
above average by months could be found in the spring and autumn months (aver-
age: population= 7095, males= 421, females= 6673). cOnclusiOns: The higher 
patient numbers for females can be clearly associated with the prevalence of 
the basic (osteoporosis) disease. It would be interesting to examine the correla-
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procured, provides alternatives to adjust the budget available and release financial 
resources for cost effective and sustainable interventions .
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Objectives: To be effective, osteoporosis (OP) therapy must be taken consistently 
and as prescribed. Persistence is critical for successful outcomes, including fracture 
risk reduction. Few studies compare the persistence of oral bisphosphonate (BPs), IV 
BPs and denosumab beyond 1 year. This retrospective database analysis evaluated 
2-year persistence to oral BPs, IV BPs and denosumab following treatment initiation 
and the risk of treatment discontinuation. MethOds: From the German IMS®LRx 
database, we included women aged ≥ 45 years who initiated an OP treatment after 
1-July-2010 (index date = treatment initiation) with ≥ 2 years of follow-up until 
31-Dec-2014. Persistence (prescription refill gap ≤ 60 days and no drug switch) was 
measured for 2 years from index date, and a Cox proportional hazard regression 
model was used to estimate the risk of treatment discontinuation (i.e. non-persis-
tence). Results: Data from 159,993 women were included in the analysis. Two years 
after treatment initiation, 39.8 % of those receiving denosumab (n= 21,154), 24.8 % 
receiving IV ibandronate (n= 20,472), 21.2 % receiving IV zoledronic acid (n= 3,966), 
and 16.7 %„Ÿ17.5 % of those receiving oral BPs were persistent. Compared with those 
receiving denosumab, women receiving IV ibandronate or IV zoledronic acid were 
at higher risk of treatment discontinuation (HR [95% CI]: 1.65 [1.61-1.69] and 1.28 
[1.23-1.33] respectively; p< 0.001 for both). Moreover, women treated with oral BPs vs 
denosumab showed a two-fold risk of treatment discontinuation (HR [95% CI]: 2.02 
[1.98-2.06] for alendronate, 2.02 [1.95-2.09] for ibandronate and 1.96 [1.91-2.01] for 
risedronate; p< 0.001 for all). cOnclusiOns: In our database study of women ini-
tiating BPs (oral or IV) or denosumab in routine clinical practice, 2-year persistence 
was highest for denosumab (1.5-2 times higher). Moreover, compared to denosumab, 
women treated with oral or IV BPs were at higher risk of treatment discontinuation. 
Such improved persistence may improve clinical outcomes, including increased 
fracture risk reduction.
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Objectives: We aim to examine the association between self-reported RD and early 
retirement by using large real-world observational data in Portugal. MethOds: We 
used individual level data from the national, population-based EpiReumaPt study 
(September 2011 to December 2013). 10,661 inhabitants were randomly surveyed in 
order to capture and characterize all cases of RD within a representative sample of 
the Portuguese population, which were stratified by administrative territorial units 
(NUTSII). In this analysis we used all participants aged between 50 and 65 years old, 
near the official retirement age (N= 2,792; females: 1,727). The association of self-
reported RD and early retirement was tested using logistic regression. All estimates 
were computed as weighted proportions, in order to take into account the sampling 
design. Results: 29.9% of the Portuguese population with ages between 50 and 64 
years old were officially retired. Among these, 43.2% were retired due to ill-health, 
which in turn about a third (30.4%) was specifically due to RD. Thus, 13.1% of all 
retirees self-reported RD as the main reason for early retirement. More than a third 
(34.2%; females: 46.3%) of all study population self-reported RD, being also more 
likely to self-report other main chronic disease (OR: 3.4; CI: 2.53-4.65; p< 0.001). 35.2% 
of RD respondents were retired versus 27.2% of those non-RD (p= 0.025). Prevalence 
of self-reported RD seems to be associated with early retirement (unadjusted OR: 
1.45; CI: 1.05-2.01; p= 0.025). Some other characteristics are also associated with 
early retirement, in particular older age, male gender and presence of other chronic 
diseases. RD association tends to be independently associated with early retire-
ment (adjusted OR: 1.41; CI: 1.03-1.95; p= 0.031). cOnclusiOns: These results are 
similar with previous data from the National Health Survey conducted in Portugal 
nearly a decade ago and confirms the impact that self-reported RD still have on 
early retirement.
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chARActeRiSticS of PAtientS StARtinG BioloGic tReAtMentS foR 
RheuMAtoid ARthRitiS in the ReAl woRld: SySteMAtic Review
Kilcher G, Didden E, Hummel N, Egger M
University of Bern, Bern, Switzerland
Objectives: To assess demographic and disease characteristics of rheumatoid 
arthritis (RA) patients starting treatment with biologic disease-modifying anti-rheu-
matic drugs (DMARDs) in observational studies. MethOds: Systematic review of 
published observational studies in adult patients with RA treated with one of three 
biologic DMARDs (etanercept, rituximab, tocilizumab). We identified eligible studies 
through electronic searches of the MEDLINE and EMBASE databases. Two reviewers 
screened the articles independently. We extracted study characteristics such as 
location and calendar period, demographics of study populations, dose, frequency 
and concomitant therapies, and baseline characteristics such as disease duration, 
the most common bone disease and its incidence is rapidly increasing with the 
aging population. Even if curable, it is often left untreated causing a moderate use 
of economic resources that could be avoided.
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Objectives: Hospital Parc Taulí and Johnson & Johnson, partnered in a program 
to design and implant a fast track program for knee joint replacement. The objec-
tive was to decrease morbidity, functional convalesce, length of stay and increase 
patient and professionals satisfaction efficiently. MethOds: The implementation 
included 3 phases and two multidisciplinary Workgroups. Clinical aspects based on 
evidence, combined with organizational optimization, resources distribution and 
process redesign. Phase I: evaluation, nourished by Kaizen methodologies, Lean 
and 6 Sigma processes, Blum and Taylor laborer environment and Alex Faicknet 
Osborn group dynamics were taken under consideration. Phase II: Implantation, 
using Taylor dynamics to define the strategies to produce improvement on target 
indicators. Phase III: Monitoring, both from length of stay, security aspects such as 
morbidity, mortality, readmission rates, patient and professional satisfaction, and 
economic impact. Results: The length of stay is influenced by factors such as 
patient profile and organizational aspects. Empowered patients are more active. 
A new patient pathway was developed, initiated when admitted to discharge and 
post-operative follow up. Improvement on healthcare results, increasing patient and 
professional’s satisfaction, and reducing 50% length of stay, resulting on significant 
economical savings. cOnclusiOns: Analyzing the patient pathway through an 
analysis methodology, reingeniery and diagnosis healthcare process (in outcomes 
and in direct cost), the patient involvement in the whole process can result not only 
in important efficiency improvement, but also improve the working environment 
and enhanced team work culture for a continuous process improvement.
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eStABliShinG the vAlue of eMeRGinG BioSiMilARS
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Objectives: The emergence of biosimilars for blockbuster therapies such as 
Remicade, Humira, Enbrel and Rituxan/MabThera is changing the paradigm by which 
traditional market access decisions are made for biologics. Furthermore, the regula-
tory pathway in Europe and the U.S. has raised uncertainties among clinicians regard-
ing both the efficacy and safety of biosimilar molecules. The objectives of our research 
were to (1) understand the evolving mechanisms for biosimilar market access, (2) 
identify the key stakeholders involved in access decisions or influence and (3) deter-
mine the value drivers of biosimilars across diverse stakeholder groups. MethOds: 
A large sample of stakeholders (n= 271) were engaged, including clinical specialists, 
payers and patients, across Europe and in the U.S. We performed in-depth qualita-
tive interviews to gain an understanding of the current landscape for biologics and 
expectations for biosimilars, focusing on RA, Ulcerative Colitis, Crohn’s Disease and 
Psoriasis. Results: Our research indicates the fundamental understanding of bio-
similars is inconsistent both within stakeholder groups and across different groups. 
Furthermore, for clinicians, a lack of accurate understanding of biosimilars can be a 
substantial driver of negative perception and a key barrier to anticipated adoption. 
Overall, each stakeholder group that will influence biosimilar market access has dif-
ferent value needs and expectations from biosimilars. cOnclusiOns: Our findings 
highlight the need for a more consistent definition of biosimilar and clinical data 
requirements and a tailored approach to value communication for key influencers 
and stakeholders in the biosimilar value chain.
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Barillas E1, Valdez C2, Narvaez E2, Vasquez G3
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Objectives: In 2014, the budget for high cost drugs in Dominican Republic (DR) was 
USD 107 million, accounting for 51% of the MoH budget for medicines. Resources 
allocated for the 2015 budget were USD 49 million, leaving a shortfall of USD 62 
million. The MoH requested technical assistance from the USAID funded SIAPS 
project to conduct an evidence based analysis of the 98 products included in the 
list. MethOds: Stage 1. Gathering of Evidence and Analysis; SIAPS consultant ana-
lyzed the therapeutic benefits and cost, and proposed 4 priority levels: Priority 1: 
Medicines included in the WHO Essential Medicine List; Priority 2: Included in the 
list of a Central America and DR procurement mechanism (COMISCA); Priority 3: Not 
included in the preceding groups but with scientific evidence of therapeutic benefits 
and approved by EMA and FDA; Priority 0: Medicines for which evidence on benefits 
was insufficient or for which better/cheaper alternatives were available. Stage 2. 
Review and approval by national scientific committee. During a two-day workshop, 
clinical specialists reviewed the proposed priority groups, consulted literature and 
proposed modifications supported by scientific evidence. Results: In the plenary 
session, the scientific committee, agreed by consensus on the final version of the 
high cost drugs list to be procured in 2015. Of the 98 medicines, 22 were on the 
WHO list and 17 were on the COMISCA; 14 of the remaining 59 medicines were also 
included because there was scientific evidence of its benefits. Total of 45 medicines 
were removed by consensus, with a budget decrease of 53 % and savings of USD 
21 million. cOnclusiOns: A review -based on evidence- followed by a consensus 
reached with clinical specialists allowed to select the number of products to be 
